Skip to main content
S&P 5007,633.77-0.05%DOW51,664.87-0.22%NASDAQ26,424.69+0.02%BTC$81,044.00+5.97%ETH$2,622.12+7.01%GOLD$4,429.20+0.67%OIL$96.00-1.27%
Smart Investors Daily
AD

NASDAQ · ADGM

Adagio Medical Holdings, Inc.

Healthcare · Medical - Devices

$0.52

Down-$0.03 (-5.75%)

Updated Sep 18, 2026, 5:46 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
15.22M
P/E ratio
-0.21
Dividend yield
0.00%
52-week range
$0.36 – $1.69
Volume
85.29K
Avg. volume
160.25K

Price performance

ADGM price history

1M range · 20 trading sessions · Daily adjusted prices

ADGM closed at $0.52 after 20 trading sessions, down 17.99% for the selected period.

Last close
$0.52
Period change
-17.99%
Period low
$0.45
Period high
$0.65
Daily close
View OHLC price history
ADGM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 17, 2026$0.5001$0.5226$0.4901$0.5285.29K
Sep 16, 2026$0.488$0.5204$0.4601$0.499185.52K
Sep 15, 2026$0.455$0.4997$0.431$0.4621313.04K
Sep 14, 2026$0.561$0.60$0.4505$0.4505471.53K
Sep 11, 2026$0.5601$0.61$0.5601$0.56127.2K
Sep 10, 2026$0.59$0.6203$0.5718$0.58100.76K
Sep 9, 2026$0.595$0.6398$0.5802$0.60569.24K
Sep 8, 2026$0.579$0.6398$0.55$0.6075180.6K
Sep 4, 2026$0.534$0.5899$0.53$0.564297.6K
Sep 3, 2026$0.54$0.5478$0.525$0.540763.78K
Sep 2, 2026$0.5249$0.5399$0.5005$0.5299233.16K
Sep 1, 2026$0.5399$0.5399$0.5025$0.512491.36K
Aug 31, 2026$0.5288$0.5498$0.485$0.5284279.8K
Aug 28, 2026$0.515$0.543$0.50$0.511230.47K
Aug 27, 2026$0.54$0.5499$0.515$0.5203120.25K
Aug 26, 2026$0.54$0.5647$0.5107$0.522329.39K
Aug 25, 2026$0.581$0.606$0.55$0.55570.64K
Aug 24, 2026$0.6402$0.6615$0.556$0.5901436.64K
Aug 21, 2026$0.63$0.6798$0.62$0.6491351.11K
Aug 20, 2026$0.629$0.6501$0.623$0.6341111.15K

Latest ADGM news

The latest Smart Investors Daily articles mentioning ADGM.

Stock researchCompany · Overview

ADGM research

Overview

Company profile and research snapshot.

Company profile

Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ADGM recent ratings
DateFirmRatingTarget
Jun 3, 2026LUCID CAPITAL MARKETSBuy—
Apr 14, 2026Piper SandlerOverweight—
Dec 2, 2025Lake StreetBuy—
Open full forecast

News briefing

Generated Sep 18, 2026, 5:00 PM

Why Is ADGM Down Today?

Adagio Medical shares declined 5.75% today despite announcing a positive clinical milestone—the first patient treatment in its IDE study for the next-generation vCLAS™ Ultra System. The stock's weakness may reflect profit-taking, broader market headwinds, or investor caution ahead of additional clinical data from the ventricular tachycardia trial.

    Bottom line: Today's decline appears disconnected from the clinical progress announced, suggesting market skepticism or profit-taking rather than fundamental deterioration. Investors should monitor upcoming trial enrollment data and safety readouts as the primary catalysts that could restore confidence in ADGM's clinical strategy and valuation.

    Yahoo · Sep 16, 2026

    Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix

    LAGUNA HILLS, Calif., September 16, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced highlights from the first patient enrolled in the Company’s study evaluating its next-generation vCLAS™ Ultra Ultra-Low Temperature Ablation ("ULTA") Ventricular Ablation System. The study is designed to support a Premarket Approval ("PMA") supplement to the Company’s PMA

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By